CEO Succession Plan Announced

Research evidence excerpt

CEO Succession Plan Announced

Update

July 27, 2026 02:26 PM GMT

Morgan Stanley & Co. LLCMSarepta Therapeutics Inc | North America Michael E Ulz

Equity Analyst

CEO Succession Plan Mike.Ulz@morganstanley.comRohit Bhasin +1 212 761-4650

Research Associate

Rohit.Bhasin@morganstanley.com +1 212 761-0534

Announced Avraham Novick

Avi.Novick@morganstanley.com +1 212 761-2231

Key Takeaways

Sarepta Therapeutics Inc (SRPT.O, SRPT US)

Appointed Michael Severino, MD as CEO effective July 28; current CEO Doug Biotechnology | United States of America

Ingram will remain an advisor through year-end 2026. Stock Rating Equal-weight

Industry View Attractive

Key catalysts ahead include Elevidys data in non-ambulatory patients by YE26, Price target $25.00

and siRNA MAD data in DM1 and FSHD patients in 2H26. Shr price, close (Jul 24, 2026) $15.68

Mkt cap, curr (mm) $1,697

We view clarity on the CEO transition as a positive, while DMD challenges 52-Week Range $25.32-10.42

continue and more data are needed to assess the potential of the siRNA pipeline.

Michael Severino appointed as next CEO. Earlier today, Sarepta announced the

appointment of Michael Severino, MD, as CEO (press release: effective July 28),

succeeding Doug Ingram, who will remain in an advisory role through YE26. Dr.

Severino has held roles across R&D, corporate strategy, and commercialization, and

was previously CEO of Tessera Therapeutics, a private company focused on gene

writing. The CEO transition comes before an eventful 2H26 and 2027 with key

catalysts ahead, including data from Elevidys in non-ambulatory DMD patients by

YE26 that could support its return to market in this population, MAD data from the

siRNA programs in DM1 and FSHD, the FDA’s February 2027 decisions on the